"Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.
[Shanghai 10 billion M&A Fund! 】The "Action Plan" proposes to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials.The policy is favorable for surprise attack and seize the opportunity to get on the bus > >
Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.
Strategy guide
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14